drugset / Trial / NCT06579287

A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control

NCT06579287

Phase 2 Active not recruiting 140 enrolled Sunhawk Vision Biotech, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to explore the safety and efficacy of SHJ002 Sterile Ophthalmic Solution relative to atropine in myopia control SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.

Timeline

Start
2025-01-22
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atropine Other / unclassified Topical
Subject SHJ002 Antisense oligonucleotide Topical

Indications